Novartis files CAR-T in Europe in broader use than Gilead rival – pharmaphorum
pharmaphorum |
Novartis files CAR–T in Europe in broader use than Gilead rival
pharmaphorum Chimeric antigen receptor T–cell (CAR-T) therapies are one-off treatments that involve harvesting a patient's T–cells, and genetically reprogramming them to fight cancer. Trial data so far show they offer a complete response – a complete absence of … Novartis files CAR–T therapy in Europe Novartis seeks European approval for cell therapy Kymriah |
